Marker Therapeutics (MRKR) Free Cash Flow (2010 - 2026)
Marker Therapeutics (MRKR) posted quarterly Free Cash Flow of -$1.4 million for Q1 2026, up 74.47% year-over-year from -$804842.1 in Q1 2025, and up 26.1% quarter-over-quarter from -$1.9 million in Q4 2025.
Marker Therapeutics (MRKR) Free Cash Flow (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Free Cash Flow for 17 consecutive years, with -$1.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 74.47% year-over-year to -$1.4 million; the TTM figure through Mar 2026 stood at -$7.9 million (up 37.02% YoY), while the FY2025 annual figure was -$12.0 million, down 10.12% from the prior year.
- Free Cash Flow rose to -$1.4 million in Q1 2026 per MRKR's latest filing, from -$1.9 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $3.7 million in Q4 2023 and bottomed at -$14.6 million in Q1 2022.
- Historically, Free Cash Flow has averaged -$3.3 million across 5 years, with a median of -$3.6 million in 2024.
- Annual changes were most pronounced in 2023 — Free Cash Flow soared 191.49% — and 2025, when it tumbled 328.47%.
- Marker Therapeutics' Free Cash Flow stood at -$4.1 million in 2022, then jumped by 191.49% to $3.7 million in 2023, then slumped by 226.04% to -$4.7 million in 2024, then surged by 59.6% to -$1.9 million in 2025, then gained by 26.1% to -$1.4 million in 2026.
- Business Quant data shows MRKR's Free Cash Flow at -$1.4 million in Q1 2026, -$1.9 million in Q4 2025, and -$2.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Marker Therapeutics | 27.04 Mn | 15.11 Mn | - | -3.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.40 Mn |
| Mar 31, 2026 | -1.40 Mn |
| Dec 31, 2025 | -1.90 Mn |
| Dec 31, 2025 | -1.90 Mn |
| Sep 30, 2025 | -2.74 Mn |
| Sep 30, 2025 | -2.74 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Mar 31, 2025 | -5.50 Mn |
| Mar 31, 2025 | -5.50 Mn |
| Dec 31, 2024 | -4.70 Mn |
| Dec 31, 2024 | -4.70 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | -3.57 Mn |
| Jun 30, 2024 | -3.57 Mn |
| Mar 31, 2024 | -3.84 Mn |
| Mar 31, 2024 | -3.84 Mn |
| Dec 31, 2023 | 3.73 Mn |
| Dec 31, 2023 | 3.73 Mn |